Result of AGM

Verona Pharma plc ("Verona Pharma" or the "Company") Result of AGM 12 June 2014, Cardiff - Verona Pharma plc (AIM: VRP), the drug developmentcompany focused on first-in-class medicines to treat respiratory diseases,announces that all resolutions proposed at the Annual General Meeting heldtoday were duly passed. A presentation on Verona Pharma made by its Chief Executive Officer, Dr.Jan-Anders Karlsson, will be available to view on the Company's websitewww.veronapharma.com. -Ends- For further information please contact: Verona Pharma plc Tel: 020 7863 3300Jan-Anders Karlsson, CEORichard Bungay, CFO WH Ireland Limited Tel: 020 7220 1666Chris FieldingNick Field FTI Consulting Tel: 020 3727 1000Julia PhillipsSimon ConwayVictoria Foster Mitchell Notes to Editors About Verona Pharma plc Verona Pharma is developing first-in-class drugs to treat respiratory disease,such as COPD, asthma and chronic, severe cough. The Company has two drugprogrammes, both of which are in Phase II. The lead programme, RPL554, is aninnovative dual phosphodiesterase (PDE) 3 and 4 inhibitor with bothbronchodilator and anti-inflammatory properties. The second programme, VRP700,is an innovative product for suppressing chronic, severe cough in patients withunderlying lung disease.